TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18403736
Drug: DP‐b99 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DP‐b99 (1 mg/kg per day for 4 days)
Study: 11808836
Drug: Sarpogrelate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate (200 mg, oral administration)
Study: 7723301
Drug: Cocaine hydrochloride
Normalized name: Cocaine Hydrochloride
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine hydrochloride 50 mg intranasally
Study: 7723301
Drug: Cocaine hydrochloride
Normalized name: Cocaine Hydrochloride
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine hydrochloride 126 mg intranasally
Study: 7723301
Drug: Sweat patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweat patch technology
Study: 7723301
Drug: Nondrug users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondrug users wearing patches
Study: 6355207
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day of amitriptyline
Study: 6355207
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day of phenelzine
Study: 31249253
Drug: Melatonin 3
Normalized name: melatonin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 3 mg administered sublingually 50 minutes before surgery
Study: 31249253
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered sublingually 50 minutes before surgery
Study: 19110224
Drug: Desvenlafaxine 150
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desvenlafaxine 150 mg/d
Study: 16398436
Drug: Qianggu capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qianggu capsules (QGC), 1 capsule (180 mg) each time, three times a day for three months
Study: 16398436
Drug: D-Cal Biocal,
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-Cal Biocal, 2 tablets (1500 mg) each time, once daily for three months
Study: 8590616
Drug: ritanserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ritanserin (10 mg)
Study: 2672380
Drug: nimesulide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: nimesulide (200 mg/day p.o.)
Study: 24196331
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (1319 nm, 1064 nm, and BroadBand Light)
Study: 21530095
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of zinc sulfate orally in water daily for 6 weeks + one capsule of vitamin B-complex + one capsule of vitamin A or E (first 10 days)
Study: 21530095
Drug: Proposed placebo-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proposed placebo-controlled trials with incremental doses of zinc sulfate along with magnesium and selenium
Study: 18505442
Drug: Iopanoic acid
Normalized name: Iopanoic Acid
DrugBank: Iopanoic acid (DB08946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iopanoic acid (IA) 3 g/day for 7 days
Study: 18505442
Drug: Carbimazole 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbimazole 30 mg/day for 1 month
Study: 9135951
Drug: Basic amino
Normalized name: Paired basic amino acid residue cleaving enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic amino acids (L-arginine 2 g/day plus L-lysine 0.5 g/day)
Study: 8031342
Drug: morphine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine (2 mg.ml‐1) with droperidol (0.2 mg.ml‐1)
Study: 8031342
Drug: morphine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine alone (2 mg.ml‐1)
Study: 3003445
Drug: Hydrochlorothiazide (HTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HTZ) administration, 25 mg 12-hrly for 18 days
Study: 27875286
Drug: Immunomodulatory formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulatory formula (IF) 400 mL/d for 10 days prior to surgery
Study: 22357739
Drug: Consumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of vitamin D and calcium-fortified soft white cheese (2 servings of 100 g daily for 6 weeks)
Study: 16320709
Drug: Dextran treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran treatment
Study: 10586393
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg intravenous infusion (18 min)
Study: 10586393
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg oral solution
Study: 10586393
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg orally administered capsule
Study: 8767364
Drug: New guidelines
Approvals — FDA: no, EMA: no, PMDA: no
Description: New guidelines for thrombolytic therapy
Study: 1841935
Drug: L-carnitine (LC)
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-carnitine (LC) 60 mg/kg
Study: 1841935
Drug: Non-treatment (NT)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment (NT)
Study: 26414022
Drug: Avagacestat (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avagacestat (50 mg/d)
Study: 26414022
Drug: Avagacestat (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avagacestat (125 mg/d)
Study: 23617621
Drug: Modified treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified treatment (ModTx)
Study: 23617621
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (StTx)
Study: 21543538
Drug: Controlled research
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled research meals with lower protein intake (0.9-1.1 g protein · kg(‐1) · d(‐1) reduced by 0.2 to 0.3 g · kg(‐1) · d(‐1))
Study: 21543538
Drug: Controlled research
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled research meals with higher protein intake (0.9-1.1 g protein · kg(‐1) · d(‐1) increased by 0.2 g · kg(‐1) · d(‐1))
Study: 19056566
Drug: Monosodium L-glutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosodium L-glutamate (MSG) added to a protein-rich liquid meal
Study: 19056566
Drug: Monosodium L-glutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosodium L-glutamate (MSG) added to a carbohydrate meal
Study: 19056566
Drug: Monosodium L-glutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosodium L-glutamate (MSG) added to noncaloric water
Study: 11407289
Drug: Ketamine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1.5 mg/kg i.v.
Study: 11407289
Drug: Thiamylal 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamylal 5 mg/kg i.v.
Study: 9427902
Drug: Continuous phenobarbital
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous phenobarbital therapy
Study: 3559333
Drug: Regimen I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen I: rifampin 600 mg once a month for 6 months with dapsone 100 mg daily
Study: 3559333
Drug: Regimen II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen II: same as Regimen I, supplemented with an additional 6 months' treatment with dapsone 100 mg daily
Study: 3559333
Drug: Regimen III:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen III: same as Regimen II, with rifampin administered daily for the first 7 days
Study: 31421394
Drug: 2.5% GS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% GS solution with 15% glucose
Study: 31421394
Drug: 25 mL
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mL of water (control) with 15% glucose
Study: 31421394
Drug: 2.5% GS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% GS solution with 0.09% aspartame
Study: 31421394
Drug: 25 mL
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mL of water (control) with 0.09% aspartame
Study: 15363053
Drug: Rapid intravenous
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid intravenous iron injection (100 mg of iron sucrose every 2 weeks)
Study: 15363053
Drug: Slow intravenous
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow intravenous iron infusion (100 mg of iron sucrose every 2 weeks)
Study: 15363053
Drug: Rapid intravenous
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid intravenous iron injection
Study: 15363053
Drug: Slow intravenous
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow intravenous iron infusion
Study: 8087930
Drug: C-type natriuretic
Normalized name: C-type natriuretic peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-type natriuretic peptide (CNP) infusion
Study: 31265187
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy expert (treatment provider)
Study: 25405570
Drug: BZA 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: BZA 20 mg
Study: 25405570
Drug: CE 0.45
Normalized name: Femtrace 0.45mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE 0.45 mg/BZA 20 mg and CE 0.625 mg/BZA 20 mg
Study: 15466104
Drug: HEDIS criteria
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEDIS criteria sensitivity for children without daily controller medications
Study: 15466104
Drug: HEDIS criteria
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEDIS criteria specificity for children without daily controller medications
Study: 26400835
Drug: Buprenorphine/naloxone (BUP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone (BUP) induction dosing patterns
Study: 23261733
Drug: Fluoxetine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine alone (Group A)
Study: 23261733
Drug: Fluoxetine and
Normalized name: fluoxetine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine and Cognitive Behavioral Therapy (CBT) (Group B)
Study: 15930064
Drug: Quality improvement
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quality improvement intervention with special resources for therapy
Study: 15930064
Drug: Quality improvement
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quality improvement intervention with special resources for medication management
Study: 14595996
Drug: T'ai Chi
Approvals — FDA: no, EMA: no, PMDA: no
Description: T'ai Chi exercise (1-hour sessions, twice weekly for 6 weeks)
Study: 10793607
Drug: Dimenhydrinate 50
Normalized name: dimenhydrinate 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimenhydrinate 50 mg administered rectally 30 min before anaesthesia
Study: 8793254
Drug: Flurbiprofen LAT
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen LAT (40 mg b.d.)
Study: 1740600
Drug: Daily supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplement of 560 +/- 16 kcal/day (17% energy from protein, 43% from carbohydrate, 40% from fat) during 12 weeks of resistance training.
Study: 1740600
Drug: No supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplement during 12 weeks of resistance training.
Study: 6442383
Drug: Oxazepam (OX)
Normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxazepam (OX) 45 mg
Study: 6442383
Drug: Diazepam (D)
Normalized name: diazepam Injectable Solution [D-Val]
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam (D) 15 mg
Study: 6442383
Drug: Nordiazepam (ND)
Normalized name: nordazepam
DrugBank: Nordazepam (DB14028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nordiazepam (ND) 15 mg
Study: 6442383
Drug: Diazepam (D)
Normalized name: diazepam Injectable Solution [D-Val]
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam (D) 5 mg
Study: 6442383
Drug: Oxazepam (OX)
Normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxazepam (OX) 15 mg
Study: 6442383
Drug: Nordiazepam (ND)
Normalized name: nordazepam
DrugBank: Nordazepam (DB14028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nordiazepam (ND) 5 mg
Study: 27075905
Drug: Vitamin B-12
Normalized name: Vitamin B-12
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B-12 intake of 1.5 μg/d (0.3, 9.7 μg/d); 60% consumed <2.4 μg/d.
Study: 20668330
Drug: Topical cyanoacrylates
Normalized name: ethyl cyanoacrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyanoacrylates applied every 3‐5 days for 3 months
Study: 21079955
Drug: Topical silicone
Normalized name: silicones Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical silicone gel applied twice a day for 3 months
Study: 11281499
Drug: 17 beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta‐estradiol 2 mg and norethisterone acetate 1 mg
Study: 9065535
Drug: Average daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average daily intake of absolute alcohol 1 to 25 g/day
Study: 9065535
Drug: Average daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average daily intake of absolute alcohol 26 to 50 g/day
Study: 9065535
Drug: Average daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average daily intake of absolute alcohol 51 to 100 g/day
Study: 9065535
Drug: Average daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average daily intake of absolute alcohol 101 to 200 g/day
Study: 9065535
Drug: Average daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average daily intake of absolute alcohol >200 g/day
Study: 27380615
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 0.5% levobupivacaine intraperitoneally
Study: 27380615
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 0.9% normal saline (placebo)
Study: 20530806
Drug: Erythropoiesis-stimulating agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoiesis-stimulating agents (ESA) dose increases
Study: 20530806
Drug: Hgb deflect(neg)
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hgb deflect(neg) and ESA dose decreases
Study: 27846903
Drug: Proton therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton therapy with concomitant standard chemotherapy (up to 66 Gy RBE, six fractions of 2 Gy RBE per week)
Study: 27846903
Drug: Photon therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photon therapy with concomitant standard chemotherapy (up to 66 Gy RBE, six fractions of 2 Gy RBE per week)
Study: 24163957
Drug: Calcium-vitamin D
Normalized name: Calcium-Vitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-vitamin D supplements (500 mg carbonate calcium plus 200 IU vitamin D3) for 9 weeks
Study: 16167418
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination (TC) cream
Study: 9060789
Drug: Lidocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine spray applied in the surgical wound
Study: 9223690
Drug: Oral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotic
Study: 6829321
Drug: Amoxycillin 1000
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 1000 mg twice a day for three days
Study: 6829321
Drug: Co-trimazine 90
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimazine 90 mg/sulphadiazine 410 mg, 2 tablets initially, then 1 tablet twice daily for three days
Study: 22278631
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of leflunomide 20 mg
Study: 22278631
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of leflunomide 20 mg
Study: 9373419
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) for psychosis, individualised, lasting nine months
Study: 1610419
Drug: solution gel
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL GEL [SaniClean Alcohol Antiseptic 80% Topical Solution Gel, Unscented (HP2463)]
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: solution gel (1% diclofenac)
Study: 1610419
Drug: emulsion gel
Normalized name: propofol lipid emulsion Injection [Propoven]
DrugBank: Coconut oil (DB14322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: emulsion gel (1% diclofenac)
Study: 3859953
Drug: Intracervical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical prostaglandin gel for cervical priming
Study: 3859953
Drug: Extra-amniotic prostaglandin
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-amniotic prostaglandin gel for labour induction
Study: 3859953
Drug: Systemic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic administration of PG
Study: 25891304
Drug: Nivolumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg)
Study: 25891304
Drug: Ipilimumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (3 mg/kg) + placebo
Study: 16455814
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 or 100 mg) during hypoxic exercise
Study: 7867112
Drug: Vecuronium 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.08 mg.kg‐1 administered into the pulmonary artery
Study: 7867112
Drug: Vecuronium 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.08 mg.kg‐1 administered into the right atrium
Study: 7867112
Drug: Vecuronium 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.08 mg.kg‐1 administered into a peripheral vein
Study: 2474049
Drug: Cod liver
Normalized name: Cod Liver Oil
DrugBank: Cod liver oil (DB11321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod liver oil (20 ml d‐1 for 6 weeks)
Study: 31285784
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day alpha-lipoic acid (ALA)
Study: 26500082
Drug: 0.25 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 g/d EPA + DHA
Study: 26500082
Drug: 0.5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/d EPA + DHA
Study: 26500082
Drug: 1.0 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g/d EPA + DHA
Study: 22885882
Drug: Symbiotic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbiotic mixture (Probinul, 5 g bid)
Study: 16239279
Drug: Alkalosis (NaHCO3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkalosis (NaHCO3, 0.3 g kg(‐1))
Study: 11716995
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg tibolone (Livial, Organon)
Study: 11716995
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 mg lactose)
Study: 7711419
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg daily) from days 1-24
Study: 7711419
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 mg daily) from days 11-21
Study: 7711419
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 mg single dose) on day 43
Study: 3415885
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 3 or 4 ml
Study: 3415885
Drug: 0.75% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% bupivacaine 2 or 3 ml
Study: 3415885
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 2 ml
Study: 3415885
Drug: 0.75% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% bupivacaine 1.3 ml
Study: 3415885
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dose of both solutions
Study: 3415885
Drug: 15-20/22.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-20/22.5 mg doses
Study: 24077970
Drug: Adherence questionnaire
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence questionnaire asking about specific antiretroviral medication
Study: 24077970
Drug: Adherence questionnaire
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence questionnaire asking about HIV medicines as a group
Study: 16286437
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium at a target dose of 750 mg/day (mean dose 800 mg/day) for 6 weeks
Study: 12402728
Drug: Early symptomatic
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early symptomatic treatment with placebo
Study: 6107409
Drug: Zinc therapy
Normalized name: PYRITHIONE ZINC 2 g in 100 g TOPICAL SOAP [Zinc Therapy]
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc therapy (zinc chloride added to the dialysate for 6 weeks)
Study: 28410176
Drug: SunProtect educational
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: SunProtect educational program delivered through a touch-screen tablet to 84 participants.
Study: 28410176
Drug: SunProtect educational
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: SunProtect educational program delivered through a touch-screen tablet.
Study: 17920552
Drug: Methods to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methods to steer the immune response away from cytotoxic responses or induce tolerance to gene therapy products.
Study: 16934684
Drug: Energy restriction
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy restriction (20 kcal/kg) with whey or casein supplement (40 g/day)
Study: 14616407
Drug: Voriconazole (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (3 mg kg‐1) administered once daily on days 1 and 12, and every 12 h on days 3‐11 (Study A)
Study: 14616407
Drug: Voriconazole (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (loading dose 6 mg kg‐1 twice on day 1, then 3 mg kg‐1 twice daily on days 2‐9, and once at 3 mg kg‐1 on day 10) (Study B)
Study: 10688417
Drug: Steroid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid group (1 g of methylprednisolone intravenously administered two hours before operation)
Study: 6613236
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg SIN 1